About Memphasys
Memphasys is a company based in Homebush (Australia) founded in 2006. Memphasys offers products and services including Felix™ System, Storage Medium, and Improved Medium. Memphasys operates in a competitive market with competitors including Cytoswim, Reproductive Solutions and ZyMot, among others.
- Headquarter Homebush, Australia
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Memphasys Limited.
-
Annual Revenue
$2.42 K (USD)-93.83as on Jun 30, 2025
-
Net Profit
-$3.23 M (USD)-11.25as on Jun 30, 2025
-
EBITDA
-$2.23 M (USD)24.38as on Jun 30, 2025
-
Latest Funding Round
$1.6 M (USD), Post-IPO
Aug 17, 2022
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Memphasys
Memphasys is a publicly listed company on the ASX with ticker symbol MEM in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Memphasys
Memphasys offers a comprehensive portfolio of products and services, including Felix™ System, Storage Medium, and Improved Medium.
Device for separating sperm from semen in IVF procedures.
Medium for long-term ambient storage of human sperm.
Medium for sperm isolation, fertilization, and cryopreservation.
People of Memphasys
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Memphasys
Investors in Memphasys
Memphasys has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Peters Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global investment firm provides professional services for community improvement and international development.
|
Locked | Locked | Locked |
Investor details for Memphasys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Memphasys
Investment portfolio details for Memphasys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Memphasys
Detailed financials for Memphasys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Memphasys Comparisons
Peer comparison for Memphasys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Memphasys
Memphasys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytoswim, Reproductive Solutions and ZyMot, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sperm selection tools for assisted reproduction are developed.
|
|
| Locked | Locked | Locked |
Developer of advanced sperm collection and processing technologies. It offers solutions for at-home semen analysis and in-clinic sperm processing, improving sperm quality and increasing the chances of successful conception. The company's products are designed to enhance sperm viability during collection, transport, and preparation for various fertility treatments, including IUI, IVF, and ICSI. These technologies aim to simplify the process for both patients and healthcare providers, improving outcomes and reducing stress. The company also provides support and resources for patients and clinics.
|
|
| Locked | Locked | Locked |
Develops innovative sperm separation devices for medical applications.
|
Detailed competitors of Memphasys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Memphasys
Complete news archive for Memphasys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Memphasys
Memphasys was founded in 2006 and raised its 1st funding round 16 years after it was founded.
Memphasys is headquartered in Homebush, Australia. It is registered at Homebush, New South Wales, Australia.
Alison Coutts is the current CEO of Memphasys.
Annual revenue of Memphasys is $2.42K as on Jun 30, 2025.
Memphasys was founded in 2006 and is based in Homebush, Australia. Operations center on biotechnology for reproductive health, where an automated electrophoretic system called the Felix device is developed. This system separates sperm from raw semen, supporting assisted reproductive technologies. The companys work addresses challenges in fertility treatments through innovative cell separation methods.
Memphasys's top competitors include Cytoswim, Reproductive Solutions and ZyMot.
Memphasys offers Felix™ System, Storage Medium, and Improved Medium.
Yes, Memphasys is publicly traded on ASX under the ticker symbol MEM.
Memphasys has 1 investor. Key investors include Peters Investment Group.
The ticker symbol of Memphasys is MEM on ASX.